Drugs / dendritic cell vaccine therapy
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01239875 | Nov 2010 → Nov 2015 | MALT lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, grade III lymphomatoid granulomatosis +6 | Mayo Clinic | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT02070406 | Jul 2014 → Dec 2018 | cancer of unknown primary site | Jonsson Comprehensive Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00004880 | Jun 1997 → Apr 2001 | kidney cancer | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01697527 | Nov 2012 → Nov 2026 expected | cancer | Jonsson Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dendritic cell vaccine therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004880 ↗ |
| Action | Activate | “The vaccine will be made using the NY-ESO-1 protein and may help to stimulate the engineered immune response to tumor cells.” NCT01697527 ↗ |
| Modality | Vaccine | “dendritic cell vaccine therapy” NCT00004880 ↗ |
| Route | Other | “Given intratumorally” NCT01239875 ↗ |